Please Wait...

Hoffman Phantom Acquisition and Analysis Methods for Qualification of PET Centers in Multicenter Neurology Clinical Trials

 

Gregory Klein, David Scott, Mehul Sampat, Joyce Suhy BioClinica, Newark, CA, USA –
email: gregory.klein@bioclinica.com

BACKGROUND

Numerous multicenter clinical trials in Alzheimer's disease use amyloid PET as a quantitative biomarker for patient enrichment during screening, and to derive longitudinal efficacy endpoints.

In this context, phantom imaging studies are crucial for reducing quantitative variability due to differences in acquisition settings and intrinsic imaging characteristics.

Phantom studies must also be used to verify that each scanner is properly calibrated and has adequate capabilities to support brain imaging.

Standards for phantom studies validating tumor imaging requirements have been well-described, and generally are focused on quantitative accuracy for uptake "hot spots" at tumor locations.

The task for amyloid PET imaging is quite different: rather than hot spots, correct interpretation of uptake differences between adjacent grey and white matter regions is the goal.

Though metrics for tumor imaging such as image uniformity and resolution recovery are still important for amyloid imaging, use of a realistic anthropomorphic phantom can be helpful in ensuring that all scanners will provide acceptable images for the study, and that scatter and attenuation correction methods work as expected.

Unfortunately, the preparation and analysis of such phantoms is not trivial. We describe methods and pitfalls for PET center qualification using the anthropomorphic 3D Hoffman phantom.

Techniques have been developed to obtain both traditional imaging metrics typical of tumor imaging, and to verify adequate brain imaging quality using a single phantom scan.

METHODS

Phantom Description

  • A digital dataset derived from the Data Spectrum 19-slice bitmap was developed to obtain a 160×160×90, 1.548×1.548×1.548 mm voxel gold standard reference volume modeling the individual sub-layers of the Hoffman phantom [1].
  • Each slice of this 90-slice phantom represents either an all grey layer with values either 0.0 or 1.0; or a grey/white layer with values either 0, 0.5 or 1.0.  When smoothed with a Gaussian filter, this model simulates the 4:1 grey matter : white matter uptake pattern typically seen in patient FDG data (Fig 1).
  • Amyloid images for negative subjects are nearly the inverse of FDG images, so the Hoffman data also provides a realistic model for amyloid imaging.

Figure 1 - Digital Hoffman Phantom

  1. 19-slice version supplied by Data Spectrum.
  2. 90-slice version modeling more accurately individual layers of each slice.
  3. smoothed version of the 90-slice digital phantom.
  4. sample real phantom data obtained from the high-resolution HRRT scanner.

Hoffman Preparation and Scanning

  • Hoffman phantoms are prepared by thoroughly mixing 0.5-0.6 mCi 18F-FDG solution in the phantom, and imaging immediately using the same acquisition and reconstruction protocol planned for use with patient imaging.
  • Phantoms are positioned in the center of the scanner's field of view in a standard orientation simulating supine patient brain imaging.

Analysis Methology

  • For phantom analysis, a 20 min portion of the scan is summed and co-registered to the digital gold standard.
  • Because the physical Hoffman phantom slice thickness is slightly variable, a scaling term is used in the co-registration process.
  • Once co-registered, effective spatial resolution is determined by fitting in-plane and axial Gaussian smoothing parameters to best match the digital model to the test phantom data [2].
  • Intensity of the test data is normalized to the gold standard using a volume of interest (VOI) specified in regions of pure grey matter, which represent the highest signal intensity in the phantom.
  • Once co-registered, smoothed and intensity normalized, a difference image is computed from which various quantitative and visual assessments can be made.
  • Additionally, standard uptake value ratio (SUVR) values are computed and compared for the digital and test datasets using a modified AAL atlas to define regions in the frontal, temporal, cingulate, occipital, parietal, and precuneus areas, normalized to whole cerebellum.
  • The data presented here have been applied to Hoffman scan data acquired as a part of the ADNI and other AD studies site qualification process.

DISCUSSION

  • The difference image and normalized Hoffman data allow computation of visual and quantitative metrics such as scanner spatial resolution, axial uniformity, grey to white matter contrast and accuracy of SUVR calculations.
  • Results also demonstrate potential pitfalls in use of the Hoffman phantom (Fig 2).
  • Proper phantom preparation is crucial to remove air bubbles that create areas of hypointensity, and to avoid non-uniformities in phantom radiotracer concentration resulting from improper mixing of the 18F solution. In such cases, it is often difficult to determine if image quality is degraded due to improper mixing, or to physical imaging issues with the scanner. Therefore, close examination of the data and in some cases a repeated Hoffman scan must be carried out to verify unacceptable results.
  • Another pitfall is that the Hoffman phantom does not completely cover the axial field of view of many scanners. For these environments, it is important to verify performance of the outer imaging planes using auxiliary data, such as from daily and periodic QA procedures, or from a separate scan of a uniform phantom.

Figure 2 - Preparation Pitfalls

  1. air bubbles
  2. point hot spot
  3. hot spot due to plane separation
  4. inadequate mixing (difference image shown)

Figure 3 - Hoffman Analysis Methods

Test data from a 20min scan are co-registered, intensity normalized, and matched for spatial resolution.
Both visual and quantitative analyses are performed on the input and difference image data.

With this analysis framework, both SUVR accuracy as well as conventional scanner image metrics such as
spatial resolution, axial uniformity and signal to noise, can be evaluated from a single phantom scan.

Figure 4 - Example Results

Top - Typical passing results
Middle - Failing results with hyperintensity in
anterior regions
Bottom - Failing results due to incorrect scatter correction method

Figure 5 - Summary data from 89 ADNI phantom scans

Equivalent Hoffman spatial resolution ranged from 3.5 - 8.9 mm

Other values seen are mean error calculated over the entire brain region, grey:white intensity level calculated within the grey/white ROIs, and the ratio of SUVR seen in one region between the digital standard and the test data

CONCLUSION

  • Use of a standardized Hoffman phantom acquisition protocol, and comparison to a high-resolution digital gold standard, allows computation of quality metrics and calibration data to reduce inter-scanner variability in multi-center brain PET imaging studies.

REFERENCES

[1] Koeppe R, Personal communications.

[2] Joshi A, et al. Reducing between scanner differences in multi-center PET studies. Neuroimage 2009;46:154–9

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (3 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (3 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (6 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (2 weeks ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (2 weeks ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen